Bienvenue sur le forum !

Si vous souhaitez rejoindre la communauté, cliquez sur l'un de ces boutons !



>> Partage d'analyses

Teva Pharmaceuticals (NASDAQ: TEVA)

Ça fait un bout que je prêche en faveur de Teva. Voici les grandes lignes des résultats dévoilés ce matin:


Q4 2011 Highlights:


  • Net revenues of $5.7 billion, compared to $4.4 billion in the fourth
    quarter of 2010, an increase of 28%.

  • Non-GAAP net income and Non-GAAP EPS of $1.4 billion and $1.59 diluted
    earnings per share, an increase of 23% and 27%, respectively, compared
    to $1.1 billion and $1.25 diluted earnings per share in the fourth
    quarter of 2010.

  • Cash flow from operations of $1.4 billion, and free cash flow of $958
    million, an increase of 30% and 33%, respectively, compared to the
    fourth quarter of 2010.


2011 Highlights


  • Net revenues of $18.3 billion, compared to $16.1 billion in 2010, an
    increase of 14%.

  • Non-GAAP net income and Non-GAAP EPS of $4.4 billion and $4.97 diluted
    earnings per share, an increase of 7% and 9%, respectively, compared
    to $4.1 billion and $4.54 diluted earnings per share in 2010.

  • Cash flow from operations of $4.1 billion.
Connectez-vous ou Inscrivez-vous pour commenter.